4.7 Review

A new horizon of precision medicine: combination of the microbiome and extracellular vesicles

Journal

EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 54, Issue 4, Pages 466-482

Publisher

SPRINGERNATURE
DOI: 10.1038/s12276-022-00748-6

Keywords

-

Funding

  1. Korean Health Technology R&D Project Grant of the Korean Health Industry Development Institute (KHIDI) funded by the Korean Ministry of Health Welfare [HR14C0001, HR16C0001]
  2. Technology Innovation Program [20013712]
  3. Ministry of Trade, Industry & Energy (MOTIE, Korea)

Ask authors/readers for more resources

The disease pattern of intractable disease has changed over time, and now involves chronic diseases with immune and metabolic dysfunction. Microbial extracellular vesicles (EVs) play a significant role in the pathogenesis of various intractable diseases and show potential as biomarkers for disease diagnosis. Microbial EV therapy has advantages over other forms of therapy.
Over several decades, the disease pattern of intractable disease has changed from acute infection to chronic disease accompanied by immune and metabolic dysfunction. In addition, scientific evidence has shown that humans are holobionts; of the DNA in humans, 1% is derived from the human genome, and 99% is derived from microbial genomes (the microbiome). Extracellular vesicles (EVs) are lipid bilayer-delimited nanoparticles and key messengers in cell-to-cell communication. Many publications indicate that microbial EVs are both positively and negatively involved in the pathogenesis of various intractable diseases, including inflammatory diseases, metabolic disorders, and cancers. Microbial EVs in feces, blood, and urine show significant differences in their profiles between patients with a particular disease and healthy subjects, demonstrating the potential of microbial EVs as biomarkers for disease diagnosis, especially for assessing disease risk. Furthermore, microbial EV therapy offers a variety of advantages over live biotherapeutics and human cell EV (or exosome) therapy for the treatment of intractable diseases. In summary, microbial EVs are a new tool in medicine, and microbial EV technology might provide us with innovative diagnostic and therapeutic solutions in precision medicine. Microbiome: Hacking microbial communication networks for clinical applications The tiny membrane-bound vesicles containing various biomolecules that the organisms comprising our microbiome release could offer a powerful tool for precision medicine. Our bodies are home to trillions of microbes, which interact closely with our tissues to maintain a healthy physiological environment. Yoon-Keun Kim of the Institute of MD Healthcare, Seoul, South Korea, and colleagues have reviewed current research into the extracellular vesicles that these microbes use to communicate with other microbes and their human hosts. The authors note that these vesicles affect tissues throughout the body, and their activities have been linked to various disorders including asthma, Crohn's disease and cancer. A deeper understanding of how these vesicles prevent or accelerate various conditions in different individuals could yield useful new diagnostic biomarkers and provide the foundation for interventions that are optimized for each patient.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available